The abstract is read at the publisher; the summary is JClub's.
In resected microsatellite-stable stage III or T4N0 colon cancer, ctDNA-positive status after surgery is linked to worse outcomes (3-year DFS 58% vs 83%; HR 2.71).
- Why it matters: Standard oxaliplatin-based adjuvant therapy can cause toxicity yet still leaves some patients relapsing, creating a need for adaptive risk-directed treatment.
- What they did: PEGASUS, a multicenter single-arm phase 2 trial, used serial post-surgery ctDNA to de-escalate or escalate CAPOX, FOLFIRI, or capecitabine, with a primary 2-year relapse-free rate in ctDNA-negative patients.
- The result: The primary endpoint was not met: with 100 ctDNA-negative cases, the 2-year relapse-free rate was 88% (90% CI 81–93%), and ctDNA-guided care showed similar DFS with substantially less neurotoxicity versus matched TOSCA controls.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.